# US 2006/0153817 A1 · Cartilage and bone repair and regeneration using postpartum-derived cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153817 A1
- Document ID: US20060153817A1
- Status: Published application
- Kind: A1
- Application number: 11/321,863
- Filed: 2005-12-29
- Published: 2006-07-13
- Earliest claimed: 2003-06-27
- Assignees: Ethicon, Inc.
- Inventors: Anthony Kihm; Agnieszka Seyda; Alexander Harmon; Ian Harris; Darin Messina; Sanjay Mistry; Anna Gosiewska; Chin-Feng Yi
- Web page: https://patentgrep.com/patent/US20060153817A1

## CPC

- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/204: {IL-6}
- A61K 38/2053: {IL-8}
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N 2500/32: Amino acids
- C12N 2500/34: Sugars
- C12N 2500/44: Thiols, e.g. mercaptoethanol
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2500/95: Protein-free medium and culture conditions
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/21: Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- C12N 2501/23: Interleukins [IL]
- C12N 2502/02: embryonic cells
- C12N 2506/02: from embryonic cells
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2509/00: Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N 2533/50: Proteins
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions.

## Claims

### Claim 1

A postpartum-derived cell comprising a cell derived from human postpartum tissue substantially free of blood, wherein said cell is capable of self-renewal and expansion in culture and has the potential to differentiate into a cell of an osteogenic or chondrogenic phenotype; wherein said cell requires L-valine for growth; wherein said cell is capable of growth in about 5% to about 20% oxygen; wherein said cell further comprises at least one of the following characteristics:
(a) production of at least one of granulocyte chemotactic protein 2 (GCP-2), reticulon 1, tissue factor, vimentin, and alpha-smooth muscle actin;
(b) lack of production of at least one of GRO-alpha or oxidized low density lipoprotein receptor, as detected by flow cytometry;
(c) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(d) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry;
(e) expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for at least one of interleukin 8;
reticulon 1; chemokine (C—X—C motif) ligand 1 (melanoma growth stimulating activity, alpha); chemokine (C—X—C motif) ligand 6 (granulocyte chemotactic protein 2); chemokine (C—X—C motif) ligand 3; and tumor necrosis factor, alpha-induced protein 3 or expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for at least one of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, clone IMAGE:4179671, hypothetical protein DKFZp564F013, downregulated in ovarian cancer 1, and clone DKFZp547K1113;
(f) expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is reduced for at least one of: short stature homeobox 2; heat shock 27 kDa protein 2; chemokine (C—X—C motif) ligand 12 (stromal cell-derived factor 1); elastin; cDNA DKFZp586M2022 (from clone DKFZp586M2022); mesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B; dishevelled associated activator of morphogenesis 2; DKFZP586B2420 protein; similar to neuralin 1; tetranectin; src homology three (SH3) and cysteine rich domain; B-cell translocation gene 1, anti-proliferative; cholesterol 25-hydroxylase; runt-related transcription factor 3; hypothetical protein FLJ23191; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer; frizzled homolog 7; hypothetical gene BC008967; collagen, type VIII, alpha 1; tenascin C; iroquois homeobox protein 5; hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2; cDNA FLJ12280 fis, clone MAMMA1001744; cytokine receptor-like factor 1; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; DKFZP586L151 protein; transcriptional co-activator with PDZ-binding motif (TAZ); sine oculis homeobox homolog 2; KIAA1034 protein; early growth response 3; distal-less homeobox 5; hypothetical protein FLJ20373; aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II); biglycan; fibronectin 1; proenkephalin; integrin, beta-like 1 (with EGF-like repeat domains); cDNA clone EUROIMAGE 1968422; EphA3; KIAA0367 protein; natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C); hypothetical protein FLJ14054; cDNA DKFZp564B222 (from clone DKFZp564B222); vesicle-associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1; BCL2/adenovirus E1B 19 kDa interacting protein 3-like; AE binding protein 1; cytochrome c oxidase subunit VIIa polypeptide 1 (muscle); neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36 kDa;
(g) secretion of at least one of monocyte chemotactic protein-1, interleukin(IL)-6, IL-8, granulocyte chemotactic protein-2, hepatocyte growth factor, keratinocyte growth factor, fibroblast growth factor, heparin binding-epidermal growth factor, brain derived neurotrophic factor, thrombopoietin, macrophage inflammatory protein (MIP)-1a, RANTES, and tissue inhibitor of matrix metalloprotease 1;
(h) lack of secretion of at least one of transforming growth factor-beta2, angiopoetin-2, platelet derived growth factor-bb, MIP1b, I309, macrophage-derived chemokine, and vascular endothelial growth factor, as detected by ELISA; and
(i) the ability to undergo at least 40 population doublings in culture.

### Claim 2 (depends on 1)

The cell of claim 1 which has been isolated from a post-partum placenta or fragment thereof by enzymatic dissociation with at least one of a matrix metalloprotease, a neutral protease, and a mucolytic enzyme that digests hyaluronic acid.

### Claim at position 3

3-20. (canceled)

### Claim 21 (depends on 1)

A cell population comprising the postpartum-derived cell of claim 1.

### Claim 22 (depends on 21)

The cell population of claim 21 wherein said cell population is substantially homogeneous.

### Claim 23 (depends on 21)

The cell population of claim 21 wherein said cell population is heterogeneous.

### Claim 24 (depends on 23)

The cell population of claim 23 further comprising at least one cell type of bone marrow cells, chondrocytes, chondroblasts, chondrocyte progenitor cells, or stem cells.

### Claim 25 (depends on 12)

A cell population comprising the postpartum-derived cell of claim 12.

### Claim 26 (depends on 25)

The cell population of claim 25 wherein said cell population is substantially homogeneous.

### Claim 27 (depends on 25)

The cell population of claim 25 wherein said cell population is heterogeneous.

### Claim 28 (depends on 27)

The cell population of claim 27 further comprising at least one cell type of bone marrow cells, chondrocytes, chondroblasts, chondrocyte progenitor cells, stem cells, or other pluripotent or multipotent cell.

### Claim at position 12

29-32. (canceled)

### Claim 33 (depends on 21)

A cell lysate prepared from the cell population of claim 21.

### Claim 34 (depends on 33)

A soluble cell fraction prepared from the cell lysate of claim 33.

### Claim 35 (depends on 25)

A cell lysate prepared from the cell population of claim 25.

### Claim 36 (depends on 35)

A soluble cell fraction prepared from the cell lysate of claim 35.

### Claim at position 17

37-38. (canceled)

### Claim 39 (depends on 21)

An extracellular matrix of the cell population of claim 21.

### Claim 40 (depends on 25)

An extracellular matrix of the cell population of claim 25.

### Claim 41

(canceled)

### Claim 42 (depends on 21)

A composition comprising the cell population of claim 21 and one or more bioactive factors.

### Claim 43 (depends on 25)

A composition comprising the cell population of claim 25 and one or more bioactive factors.

### Claim 44

(canceled)

### Claim 45 (depends on 42)

The composition of claim 42 wherein said bioactive factor is a chondrogenic differentiation-inducing factor.

### Claim 46 (depends on 42)

The composition of claim 42 wherein said bioactive factor is an osteogenic differentiation-inducing factor.

### Claim 47 (depends on 1)

A pharmaceutical composition comprising a cell of claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 27

48-49. (canceled)

### Claim 50 (depends on 39)

A pharmaceutical composition comprising the extracellular matrix of claim 39 and a pharmaceutically acceptable carrier.

### Claim 51 (depends on 40)

A pharmaceutical composition comprising the extracellular matrix of claim 40 and a pharmaceutically acceptable carrier.

### Claim 52

(canceled)

### Claim 53 (depends on 33)

A pharmaceutical composition comprising the lysate of claim 33 and a pharmaceutically acceptable carrier.

### Claim 54 (depends on 35)

A pharmaceutical composition comprising the lysate of claim 35 and a pharmaceutically acceptable carrier.

### Claim 55

(canceled)

### Claim 56 (depends on 1)

A cell culture comprising at least one cell of claim 1 in a culture medium.

### Claim 57 (depends on 56)

The cell culture of claim 56 wherein said culture medium comprises chondrogenic medium or osteogenic medium.

### Claim 58 (depends on 56)

The cell culture of claim 56 further comprising at least one chondrogenic differentiation-inducing agent.

### Claim 59 (depends on 58)

The cell culture of claim 58 wherein said chondrogenic differentiation-inducing agent is at least one of transforming growth factor-beta3 or growth and differentiation factor-5.

### Claim 60 (depends on 56)

The cell culture of claim 56 further comprising at least one osteogenic differentiation-inducing agent.

### Claim 61 (depends on 60)

The cell culture of claim 60 wherein said osteogenic differentiation-inducing agent is at least one of transforming growth factor-beta 1, bone morphogenic protein (BMP)-2, or BMP4.

### Claim 62 (depends on 21)

A matrix comprising a cell population of claim 21.

### Claim 63 (depends on 25)

A matrix comprising a cell population of claim 25.

### Claim 64

(canceled)

### Claim 65 (depends on 62)

The matrix of claim 62 wherein said matrix comprises a three-dimensional scaffold.

### Claim 66 (depends on 63)

The matrix of claim 63 wherein said matrix comprises a three-dimensional scaffold.

### Claim at position 45

67-89. (canceled)

### Claim 90 (depends on 1)

A kit comprising at least one cell of claim 1 and at least one additional component of a matrix, a hydrating agent, a cell culture substrate, a differentiation-inducing agent, and cell culture media.

### Claim 91 (depends on 90)

The kit of claim 90 wherein said matrix is a three-dimensional scaffold.

### Claim 92 (depends on 91)

The kit of claim 91 wherein said cell is seeded on said scaffold.

### Claim 93 (depends on 90)

The kit of claim 90 wherein said differentiation-inducing agent is an osteogenic differentiation-inducing agent or a chondrogenic differentiation-inducing agent.

### Claim at position 50

94-96. (canceled)

### Claim 97 (depends on 47)

The pharmaceutical composition of claim 47 wherein said composition comprises an effective amount of said cells to treat a bone or cartilage condition.

### Claim at position 52

98-99. (canceled)

### Claim 100 (depends on 50)

The pharmaceutical composition of claim 50 wherein said composition comprises an effective amount of said extracellular matrix to treat a bone or cartilage condition.

### Claim 101 (depends on 51)

The pharmaceutical composition of claim 51 wherein said composition comprises an effective amount of said extracellular matrix to treat a bone or cartilage condition.

### Claim 102

(canceled)

### Claim 103 (depends on 53)

The pharmaceutical composition of claim 53 wherein said composition comprises an effective amount of said lysate to treat a bone or cartilage condition.

### Claim 104 (depends on 54)

The pharmaceutical composition of claim 54 wherein said composition comprises an effective amount of said lysate to treat a bone or cartilage condition.

### Claim 105

(canceled)

### Claim 106 (depends on 47)

The pharmaceutical composition of claim 47 further comprising at least one other cell type of stem cells, bone marrow cells, chondrocytes, chondroblasts, osteocytes, osteoblasts, osteoclasts, bone lining cells, and other bone or cartilage progenitor cells.

### Claim at position 60

107-108. (canceled)
